Pele Chong

List of Publications by Year
in descending order

37 papers	1,318 citations	331670 21 h-index	345221 36 g-index
37 all docs	37 docs citations	37 times ranked	1281 citing authors

#	Article	IF	Citations
1	Enhancing enterovirus A71 vaccine production yield by microcarrier profusion bioreactor culture. Vaccine, 2018, 36, 3134-3139.	3.8	11
2	Mucosal delivery of a combination adjuvant comprising emulsified fine particles and LD-indolicidin enhances serological immunity to inactivated influenza virus. Microbes and Infection, 2016, 18, 706-709.	1.9	6
3	Development of a full-length cDNA-derived enterovirus A71 vaccine candidate using reverse genetics technology. Antiviral Research, 2016, 132, 225-232.	4.1	11
4	Immunological and biochemical characterizations of coxsackievirus A6 and A10 viral particles. Antiviral Research, 2016, 129, 58-66.	4.1	33
5	Degradable emulsion as vaccine adjuvant reshapes antigen-specific immunity and thereby ameliorates vaccine efficacy. Scientific Reports, 2016, 6, 36732.	3.3	14
6	Recombinant lipidated dengue-3 envelope protein domain III stimulates broad immune responses in mice. Vaccine, 2016, 34, 1054-1061.	3.8	19
7	Depletion of regulatory T-cells leads to moderate B-cell antigenicity in respiratory syncytial virus infection. International Journal of Infectious Diseases, 2015, 41, 56-64.	3.3	8
8	Is a multivalent hand, foot, and mouth disease vaccine feasible?. Human Vaccines and Immunotherapeutics, 2015, 11, 2688-2704.	3.3	55
9	Recombinant Adeno-Vaccine Expressing Enterovirus 71-Like Particles against Hand, Foot, and Mouth Disease. PLoS Neglected Tropical Diseases, 2015, 9, e0003692.	3.0	19
10	Review of Enterovirus 71 Vaccines. Clinical Infectious Diseases, 2015, 60, 797-803.	5.8	116
11	Long-Term Immunogenicity Studies of Formalin-Inactivated Enterovirus 71 Whole-Virion Vaccine in Macaques. PLoS ONE, 2014, 9, e106756.	2.5	8
12	Toll-Like Receptor 9-Mediated Protection of Enterovirus 71 Infection in Mice Is Due to the Release of Danger-Associated Molecular Patterns. Journal of Virology, 2014, 88, 11658-11670.	3.4	35
13	Immunogenicity Studies of Bivalent Inactivated Virions of EV71/CVA16 Formulated with Submicron Emulsion Systems. BioMed Research International, 2014, 2014, 1-8.	1.9	16
14	A Purified Recombinant Lipopeptide as Adjuvant for Cancer Immunotherapy. BioMed Research International, 2014, 2014, 1-10.	1.9	5
15	Delivery of Human EV71 Receptors by Adeno-Associated Virus Increases EV71 Infection-Induced Local Inflammation in Adult Mice. BioMed Research International, 2014, 2014, 1-12.	1.9	2
16	Recombinant lipidated dengue-4 envelope protein domain III elicits protective immunity. Vaccine, 2014, 32, 1346-1353.	3.8	32
17	Prospect and challenges for the development of multivalent vaccines against hand, foot and mouth diseases. Vaccine, 2014, 32, 6177-6182.	3.8	62
18	Disintegration and cancer immunotherapy efficacy of a squalane-in-water delivery system emulsified by bioresorbable poly(ethylene glycol)-block-polylactide. Biomaterials, 2014, 35, 1686-1695.	11.4	27

#	Article	IF	Citations
19	A novel emulsion-type adjuvant containing CpG oligodeoxynucleotides enhances CD8+ T-cell-mediated anti-tumor immunity. Journal of Controlled Release, 2014, 173, 158-165.	9.9	44
20	The Madin-Darby canine kidney cell culture derived influenza A/H5N1 vaccine: A Phase I trial in Taiwan. Journal of Microbiology, Immunology and Infection, 2013, 46, 448-455.	3.1	10
21	Enzymatic Stability and Immunoregulatory Efficacy of a Synthetic Indolicidin Analogue with Regular Enantiomeric Sequence. ACS Medicinal Chemistry Letters, 2013, 4, 522-526.	2.8	6
22	Formulation and immunological evaluation of a trivalent vaccine comprising emulsified submicron particles and inactivated virions of H5N1/EV71/JEV. Human Vaccines and Immunotherapeutics, 2013, 9, 2378-2385.	3.3	6
23	Human SCARB2 Transgenic Mice as an Infectious Animal Model for Enterovirus 71. PLoS ONE, 2013, 8, e57591.	2.5	86
24	Protective Efficacy of VP1-Specific Neutralizing Antibody Associated with a Reduction of Viral Load and Pro-Inflammatory Cytokines in Human SCARB2-Transgenic Mice. PLoS ONE, 2013, 8, e69858.	2.5	19
25	Production of EV71 vaccine candidates. Human Vaccines and Immunotherapeutics, 2012, 8, 1775-1783.	3.3	64
26	Immunological Evaluation and Comparison of Different EV71 Vaccine Candidates. Clinical and Developmental Immunology, 2012, 2012, 1-8.	3.3	29
27	Human SCARB2-Mediated Entry and Endocytosis of EV71. PLoS ONE, 2012, 7, e30507.	2.5	62
28	Immunological and Biochemical Characterization of Coxsackie Virus A16 Viral Particles. PLoS ONE, 2012, 7, e49973.	2.5	48
29	Recombinant Lipidated HPV E7 Induces a Th-1-Biased Immune Response and Protective Immunity against Cervical Cancer in a Mouse Model. PLoS ONE, 2012, 7, e40970.	2.5	42
30	Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine, 2011, 29, 4362-4372.	3.8	158
31	Recombinant Trimeric HA Protein Immunogenicity of H5N1 Avian Influenza Viruses and Their Combined Use with Inactivated or Adenovirus Vaccines. PLoS ONE, 2011, 6, e20052.	2.5	48
32	Development of a quantitative enzyme linked immunosorbent assay for monitoring the Enterovirus 71 vaccine manufacturing process. Journal of Virological Methods, 2011, 176, 60-68.	2.1	23
33	Rapid isolation and characterization of bacterial lipopeptides using liquid chromatography and mass spectrometry analysis. Proteomics, 2011, 11, 2620-2627.	2.2	28
34	Emulsified Nanoparticles Containing Inactivated Influenza Virus and CpG Oligodeoxynucleotides Critically Influences the Host Immune Responses in Mice. PLoS ONE, 2010, 5, e12279.	2.5	37
35	A recombinant lipoprotein containing an unsaturated fatty acid activates NF-ÎºB through the TLR2 signaling pathway and induces a differential gene profile from a synthetic lipopeptide. Molecular Immunology, 2010, 47, 2015-2021.	2.2	46
36	Enhancement of potent antibody and T-cell responses by a single-dose, novel nanoemulsion-formulated pandemic influenza vaccine. Microbes and Infection, 2009, 11, 654-660.	1.9	17

#	Article	IF	Citations
37	A novel technology for the production of a heterologous lipoprotein immunogen in high yield has implications for the field of vaccine design. Vaccine, 2009, 27, 1400-1409.	3.8	66